Aulitzky W, Frick J, Fuchs D, Hausen A, Reibnegger G, Wachter H
Cancer. 1985 Mar 1;55(5):1052-5. doi: 10.1002/1097-0142(19850301)55:5<1052::aid-cncr2820550521>3.0.co;2-9.
The urinary neopterin excretion was measured by high-performance liquid chromatography in 417 healthy subjects and in 76 patients with clinically and pathohistologically verified neoplasias of the urinary tract (bladder tumor, carcinoma of the prostate, and renal cell carcinoma). The patients with early tumor stages both with bladder tumor and carcinoma of the prostate had normal urinary neopterin levels, except one patient with bladder tumor who had a value at the upper confidence limit. Of 40 patients with higher stages of bladder tumor and carcinoma of the prostate, 35 had elevated urinary neopterin levels. Two of 10 patients with bladder tumor in stage T3, 1 of 4 patients with carcinoma of the prostate Stage C, and 2 of 15 patients with prostatic cancer Stage D showed normal neopterin levels. The patients with renal cell carcinoma did not demonstrate any definite correlation between tumor stage and urinary neopterin excretion. The current study suggests that the neopterin assay may supplement laboratory measurements in tumors of the urinary tract, providing helpful information regarding case selection for the most convenient therapeutic management and postoperative follow-up.
采用高效液相色谱法测定了417名健康受试者以及76例经临床和病理组织学证实患有泌尿系统肿瘤（膀胱肿瘤、前列腺癌和肾细胞癌）患者的尿新蝶呤排泄量。早期膀胱肿瘤和前列腺癌患者的尿新蝶呤水平正常，但有1例膀胱肿瘤患者的值处于置信上限。在40例膀胱肿瘤和前列腺癌晚期患者中，35例尿新蝶呤水平升高。10例T3期膀胱肿瘤患者中有2例、4例C期前列腺癌患者中有1例、15例D期前列腺癌患者中有2例新蝶呤水平正常。肾细胞癌患者的肿瘤分期与尿新蝶呤排泄之间未显示出任何明确的相关性。当前研究表明，新蝶呤检测可能会补充泌尿系统肿瘤的实验室检测，为最便捷的治疗管理和术后随访的病例选择提供有用信息。
